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1. The only gastrin-dependent gastric endocrine cells are the fundic ECL cells.
Excessive hypergastrinemia stimulates ECL cell proliferation in animals and
man. The growth ofother gastric endocrine cells is regulated by the gastric pH.
2. Hypergastrinemia in man results in diffuse and linear hyperplasia ofthe ECL
cells, while micronodular hyperplasia is correlated to the grade of corpus gas-
tritis. ECLcell dysplasia and gastric carcinoids in man have been observed only
in patients with gastrinoma as part ofthe MEN I syndrome and with pernicious
anemia.
3. Gastrin dependence of GI adenocarcinoma has not been established.
Experimental findings may be explained by the presence of gastrin receptors
and the role of gastrin as an autocrine growth factor.
4. Epidemiological data do not support gastrin dependence of carcinoma ofthe
stomach, the pancreas and the colon.
INTRODUCTION
About nine years ago, Borch published his observations on an increasing number of
gastric carcinoids in patients with pernicious anemia [1-3], and toxicologists, their find-
ings of gastric carcinoids after life-long treatment with potent inhibitors of gastric secre-
tion [4, 5]. These findings were immediately connected, called the achlorhydria carcinoid
sequence and related to the accompanying hypergastrinemia [2, 6, 7, 8]. In the following
years, the question has been frequently asked whether long lasting hypergastrinemia may
initiate or promote tumor growth in man [9]. Hypergastrinemia occurs in man in the rare
event ofagastrin-producing tumor, i.e., Zollinger-Ellison syndrome (gastrinoma) or more
frequently as a consequence of hypo- or achlorhydria.
Any means of elevating the pH of the stomach content toward neutral leads to an
increase ofthe serum concentration ofgastrin, because the antral G-cell is inhibited by the
acid pH in the gastric lumen, the so-called gastrin-acid-feedback regulation, or the acid
brake [9]. This inhibition of the G-cells (which are usually stimulated by nutrients and
nerves) is partially a direct effect of acid pH in the gastric lumen and partially mediated
via paracrine secretion of somatostatin from the D-cells, which are stimulated by acid pH
(Figure 1).
If the pH in the antral lumen becomes neutral by surgical or pharmacological elimi-
nation of acid secretion, the acid brake is lost. This leads to uninhibited gastrin secretion
since G-cell stimulation by nerves and nutrients continues (Figure 2).
This review will discuss the consequences ofhypergastrinemia for the growth ofgas-
tric endocrine cells and the possible role of hypergastrinemia for tumor growth in the
stomach, the pancreas and the colon. While the growth of gastric endocrine cells in
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Figure 1. Scheme of the stimulating and inhibitory pathways regulating gastrin and acid
secretion: the acid brake. From Ref. 9, with permission.
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Figure 2. Scheme of the consequences ofneutral pH in the gastric lumen. The loss of the acid
brake results in uninhibited gastrin secretion ifG cell stimulation by nerves and nutrients continues.
Possible reasons for interruption of acid production are indicated in the lower right corner. From
Ref. 9, with permission.
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hypergastrinemic states has been extensively studied in man, the possible role of hyper-
gastrinemia for tumor growth is a hypothesis that is poorly supported by the available
clinical data.
GASTRIC ENDOCRINE CELL PROLIFERATION
The growth-promoting effect of gastrin on the histamine-producing enterochromaf-
fin-like (ECL)b cells, especially ofrodents, is known from the work ofHakanson and co-
workers [10] and is also found in other species, including man in case of atrophic typeA
(autoimmune) gastritis [3]. However, the development of gastric carcinoids described in
ahigh percentage offemale rats treated for two years with omeprazole [5] alarmed the sci-
entific community and the authorities because a direct cancerogenic effect ofomeprazole
was suspected [7]. The finding was related to the occurrence of carcinoids in pernicious
anemia, i.e., after excessive hypergastrinemia for more than ten years in five percent of
patients with an autoimmune type gastritis [2] or in patients with the MEN I syndrome and
hypergastrinemia due to a gastrinoma [ 1].
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Figure 3. Volume density ofG cells (top) and D cells (bottom) in the antral mucosa ofpatients
underlong-term omeprazole therapy. SEM values are indicated by horizontal bars. From Ref. 21,
with permission.
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However, in these two conditions, special factors are present: genetic predisposition
in the multiple endocrine neoplasia syndrome [12] and immunological factors in perni-
cious anemia [8, 9]. The dependence ofthe carcinoid development in rats from the induc-
tion of hypergastrinemia via hypochlorhydria and not a specific drug has been convinc-
ingly shown by production of carcinoids by 75 percent corpectomy [13] or feeding with
2000 mg/kg ranitidine [14]. Also, other substances like the H2 receptor antagonist loxti-
dine [4] and the hypolipidemic compound ciprofibrate [15], which inhibits gastric secre-
tion, have been shown to produce gastric carcinoids in rats. On the other hand, antrecto-
my prevents the omeprazole-induced ECL cell hyperplasia in rats, proving the mediator
role of gastrin [16]. Despite this, some authors speculate on a direct cancerogenic effect
of omeprazole [7] or on bacterial overgrowth in the achlorhydric stomach generating
genotoxic N-nitroso compounds [17]. Since rats are prone to develop endocrine tumors
and may serve as a model for MEN I syndrome [18], an inherited genetic trait might be a
prerequisite for the development of gastric ECL cell carcinoids in rats with life-long
hypergastrinemia.
In order to decide the question whether similar changes ofthe gastric endocrine cells
occurin man during long-term treatment withomeprazole, the growth ofgastric endocrine
cells has been monitored, bothquantitatively [9, 19, 20, 21] andqualitatively [20, 21, 22],
in serial gastric biopsies of patients with ranitidine-resistant peptic ulceration who were
treated with 20 to 40 mg omeprazole daily for up to eight years.
No significantquantitative changes ofthe antral G- and D-cells have been found even
after years of high-dose omeprazole treatment (Figure 3) [19, 21], while after proximal
selective vagotomy, a significant increase ofantral G-cells has been reported [23]. In rats,
the G-cell volume density doubledboth quantitatively [9, 19, 20, 21] andqualitatively [20,
21, 22] after four weeks oftreatment with omeprazole, reaching a plateau thereafter [24].
The evaluation of the ECL-cell growth has been done in sections of the oxyntic
mucosa stained with the Grimelius-silver-impregnation technique [25]. Most of the argy-
rophil cells stained with this technique are ECL-cells. Morphometric assessment ofbiopsy
samples showed an increase in gastric argyrophil cell volumedensity between the third and
fifth year of omeprazole therapy (Figure 4), but this was only significant in the group of
patients with the highest serum gastrin levels ofmore than 240 pg/ml (four times the upper
normal limit) [20]. No significant increase was seen in patients with normal or moderate-
ly elevated (below 240 pg/ml) serum gastrin levels, i.e., in 77 percent of 66 unoperated
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Figure 4. Volume density ofargyrophil cells in the oxyntic mucosa ofpatients with ranitidine-
resistant ulcerations under long-term omeprazole therapy (mean + SEM). The number of
patients evaluated is given in each column. Left, unoperated patients; right, antrectomized patients.
From Ref. 21, with permission
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study patients (Figure 5). In eight antrectomized patients, no significant increase of the
argyrophil cells has been found (Figure 4). Thus, the morphometric data support earlier
findings [9] that an increase ofthe ECL-cell volume density is correlated to elevated fast-
ing serum gastrin levels (Figure 6). A significant elevated volume density of argyrophil
cells in the oxyntic mucosa has also been described in 31 patients after selective proximal
vagotomy (one to 15 years; median, four years earlier) together with elevated fasting serum
gastrin levels [23].
The growth ofthe argyrophil cells has been also qualitatively graded according to the
classification ofSolcia et al. [26]. This classification distinguishes normal argyrophil cells
(grade 0), diffuse hyperplasia (grade 1), linear hyperplasia (grade 2), micronodular hyper-
plasia (grade 3) and adenomatoid hyperplasia (grade 4). Addition of the findings in each
patient revealed that significantly higher grades of hyperplasia occurred only in patients
with serum gastrin levels greater than 240 pg/ml. In other words, linear and micronodular
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Figure 5.Argyrophil cell volume densi-
ty in the nonantral gastric mucosa of
patients with peptic ulceration under-
going long-term omeprazole therapy.
The patients are divided into three groups
according to the mean fasting serum gas-
trin levels. A significant increase in gas-
tric argyrophil cell volumedensity occurs
only in patients with mean serum gastrin
levels greater than 240 pglml. From Ref.
20, with permission.
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Figure 6. Correlation between argyrophil
cell volume densities and individual mean
serum gastrin concentrations throughout
long-term omeprazole therapy. A, three
years of continuous omeprazole therapy; B,
four years; C, five years. From Ref. 21, with
permission.
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hyperplasia was confined to the group of patients with the highest serum gastrin levels
[20]. Dysplasia (according to the classification ofSolcia et al. [26]) has notbeen observed
in any ofthe biopsies from 655 biopsy dates. This is in complete agreement with the find-
ing in another study on more than 2000 biopsies from 448 patients treated with 20 mg
omeprazole for up to four years [22].
During the qualitative assessment of the biopsies, a progressive increase in preat-
rophic and atrophic gastritis was noticed over the study period [9, 21, 22], and a correla-
tion between different grades ofatrophy ofthe oxyntic mucosa and argyrophil cell growth
was established. By evaluating more than 3000 biopsies from 655 biopsy dates of 74
patients on long-term omeprazole treatment (up to eight years with 40 mg daily), it was
found [20] that the prevalence ofmicronodular hyperplasia in superficial corpus gastritis
was low (3.6 percent) and increased to 19.6 percent in interstitial gastritis and to 48 per-
cent in atrophic gastritis (Figure 7). This finding is in agreement with an independent
study on 2000 biopsies ofpatients treated with 20 mg daily for up to four years [22] and
suggests a causal relationship between atrophic gastritis and micronodular hyperplasia.
This relationship may partially be explained by condensation of the endocrine cells,
caused by atrophy ofthe gastric glands and, thus, may not represent true hyperplasia [22,
26].
These observations suggest that the increased occurrence ofargyrophil cell hyperpla-
sia, especially the linear and micronodular form, in patients with the highest serum gastrin
levels could as well be due to the more severe form of(atrophic) gastritis. This conclusion
is supported by studies from Estonia in patients with long-standing, untreated gastric ulcer
disease [28, 29]. None of these patients had ever received antisecretory therapy, and only
30 percent had hypergastrinemia. However, the majority (62 percent) had atrophic corpus
micronodular hyperplasla
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Figure 7. Prevalence of micronodular hyperplasia of argyrophil cells in 655 gastric biopsy
dates (four to six biopsies per date) of 74 patients treated with long-term omeprazole, 40 mg
daily. Absolute numbers are given on top of the columns. From Ref. 20, with permission.
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Figure 8. Flow sheet to explain the development ofincreased endocrine cell volume density by
two different mechanisms. First, endocrine (argyrophil) cell condensation resulting from atrophy
of gastric glands in gastritis; second, argyrophil cell hyperplasia resulting from hypergastrinemia
(Zollinger-Ellison syndrome [ZES] or typeA fundic gastritis). The former appears as micronodular
hyperplasia, the latter predominately as diffuse or linear endocrine cell hyperplasia. The dotted line
refers to ZES in patients with MEN I. From Ref. 20, with permission.
gastritis, which correlated to the incidence ofargyrophil cell hyperplasia (45 percent sim-
ple, 18 percent linear and 37 percent micronodular) [29].
It is ofinterest that the argyrophil cell hyperplasia observed in hypergastrinemic sub-
jects without corpus gastritis, i.e., gastrinoma patients, is different: in these patients the
growth of the argyrophil cells follows the pattern of simple (diffuse) or linear hyperpla-
sia, and no micronodules are found [30]. The only exception are patients with the MEN I
syndrome, who are genetically prone to develop multiple endocrine tumors [11]. This
growth pattern did not change, and no further increase of the number of argyrophil cells
during high-dose omeprazole therapy ofthe gastrinoma patients for many years occurred
[30, 31].
In a recent study, Cadiot et al. [32] described in 21 patients with gastrinoma, treated
long-term with omeprazole, a correlation of the fundic argyrophil cell densities with
serum gastrin levels. These were closely related to gastrinoma growth. Gastric carcinoids
were found only in three patients, all three having multiple endocrine neoplasia type I
(MEN I).
The available data on the interrelationship between increased argyrophil cell growth
in the corpus mucosa, gastritis and hypergastrinemia can be summarized as follows: long-
lasting excessive hypergastrinemia induces only diffuse and linear hyperplasia of the
argyrophil cells in the oxyntic mucosa, while atrophic gastritis leads to micronodular
hyperplasia [20] (Figure 8). Accordingly, a moderate hypergastrinemia in some patients
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on high-dose omeprazole therapy is without consequence for the argyrophil cell growth
and not responsible for micronodular hyperplasia.
HYPERGASTRINEMIAAND TUMOR GROWTH
Gastric ECL-cell carcinoids
The finding of carcinoids after life-long excessive hypergastrinemia in rats and
patients with pernicious anemia established the so-called achlorhydria-hypergastrinemia-
carcinoid sequence [8], and the question has been asked whether hypergastrinemia is dan-
gerous [7]. No facts have been presented until now to support this contention.
It is now well established thatgastric ECL-cell carcinoids are gastrin dependent. They
have been observed only in patients with long lasting pernicious anemia or MEN I syn-
drome with gastrinoma. ECL-carcinoids arise exclusively in the non-antral mucosa and
are relatively benign. In contrast, sporadic gastric carcinoids are mostly multihormonal
tumors and gastrin independent, i.e., found in normogastrinemic patients without any
background gastropathy [33]. They may be localized in the antrum as well as in the oxyn-
tic mucosa. With their fast growth and metastasis, they behave like neuroendocrine carci-
nomas. The claim that diffuse gastric carcinomas are neuroendocrine gastrin-dependent
tumors ("ECL-omas") [34] is pure speculation, because ECL-cells have not been con-
vincingly identified in diffuse carcinomas [35], while the occurrence of some argyrophil
cells is a frequent finding in gastric carcinomas.
Gastric adenocarcinoma
Gastrin dependence ofgastric adenocarcinomas has not been established. As in many
other tumors, gastrin receptors have been found on the cells of some gastric carcinomas.
Also, growth stimulation by gastrin of such tumors has been described in vitro and in
xenografts in vivo [36]. However, a clinical significance of this finding is not apparent
from present epidemiological data.
The increased prevalence ofpernicious anemia in patients with gastric adenocarcino-
ma [37] and of gastric carcinoma in patients with pernicious anemia [37, 38] has led to
the speculation that hypergastrinemia may be responsible for this. However, a correlation
to serum gastrin levels cannot be found in the majority of patients with gastric cancer,
while a correlation to chronic atrophic gastritis is always present. Gastroscopic screening
in achlorhydric patients revealed adenocarcinoma in four percent, but opposite to gastric
carcinoids, no correlation to hypergastrinemia [1, 40].
The five-fold risk to develop stump carcinoma after antrectomy for treatment of
recurrent ulcer disease [41, 42] occurs in the presence of even lower than normal gastrin
levels and is identical to the cancer risk after vagotomy, i.e., in the presence of elevated
serum gastrin levels [42].
Pancreatic adenocarcinoma
Despite the low affinity of gastrin to cholecystokinin A receptors of the pancreas, a
possible role ofgastrin for development and growth ofpancreatic carcinoma has been dis-
cussed. In recent experiments, pancreatic hypertrophy and atypical acinar cell foci have
been found in rats made hypergastrinemic by fundectomy for 14 months [43]. These
changes were less marked than in rats with elevated plasma levels of CCK, induced by
pancreatico-biliary diversion. Rats subjected to this procedure, but not fundectomized,
also developed pancreatic adenoma.
These observations are in contradiction to short-term studies (up to 10 weeks) that
did not show trophic effects ofendogenous or exogenous gastrin on the pancreas [44, 45,
46]. Therefore, factors other than hypergastrinemia may have been responsible for the
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pancreatic hypertrophy in the long-term fundectomized rats. The risk for cancer of the
pancreas in 5161 hypergastrinaemic patients with pernicious anemia was lower than
expected (standardized incidence ratio = 0.72) [39].
Adenocarcinoma ofthe colon
Contrary to the general opinion, gastrin has no trophic effects in the gastrointestinal
tract outside the acid producing (oxyntic) mucosa [44, 45, 46]. This has been document-
ed in chickens and several rodents. The beliefthat gastrin is ageneral trophic agent forthe
whole ofthe digestive tract and the pancreas [47, 48] is based largely on experiments with
massive doses ofpentagastrin. However, pentagastrin stimulates not only gastrin but also
CCKA receptors.
The numerous experimental data about the effect of (penta)gastrin on colon cancer
cell lines in vitro or tumor transplants in vivo [49-52] are partly contradictory and can be
explained with the frequent expression of gastrin receptors on tumor cells [53] (together
with the expression ofnumerous other peptide and steroid receptors) and the possible role
of gastrin as an autocrine growth factor in some of these tumors [9]. A recent paper
demonstrated that omeprazol-induced hypergastrinemia did not influence the growth of a
transplantable mouse colon carcinoma expressing gastrin receptors [52]. The growth-pro-
moting effect ofgastrin on a colon cancer cell line described in another recent publication
[53] was achieved with supraphysiological gastrin concentrations and was not dose-
dependent. The result mayjust indicate a conditioning role ofgastrin for optimal growth.
Fasting serum gastrin
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Figure 9. Individual values of fasting gastrin from 77 consecutive patients who underwent
total colonoscopy and showed normal mucosa (mean age, 55 years), 76 patients with benign
polyps of the colon (mean age, 62 years) and 56 patients with carcinoma of the colon (mean
age, 66 years). The horizontal line indicates the upper limit ofnormal gastrin values. From Ref. 9,
with permission.
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The prevalence ofpernicious anemia in 1777 patients with colon cancer was 0.2 per-
cent, i.e., not significantly higher than in the general population of Denmark [37]. Also,
the prevalence ofcolorectal carcinoma in patients with pernicious anemia was not signif-
icantly higher than expected in two historical studies [39, 55].
Several studies have been performed about plasma gastrin levels of patients with
polyps and carcinoma ofthe colon, because in one small investigation, significantly high-
er fasting plasma levels of gastrin had been observed in patients with colon polyps and
even higher levels in patients with colorectal adenocarcinoma than in matched controls
with normal colon [56]. In the following studies [9, 57, 58, 59], no difference was found
between matched controls with endoscopically normal colon and patients with polyps or
carcinoma of the colon (Figure 9).
Two groups described elevated serum gastrin levels in a few patients with colon car-
cinoma. However, the elevated fasting [60] and postprandial [61] serum gastrin levels
became normal after resection of the colon tumor, suggesting that the hypergastrinemia
was a consequence and not the cause of the colon tumor. The expression of gastrin mes-
senger RNA and the presence ofprogastrin and other G-17 precursors have recently been
demonstrated in 12 colon carcinomas [62]. Only one tumor contained carboxyamidated,
i.e., biologically active, gastrins. This finding would explain the elevated, and after tumor
resection, normalized serum gastrin levels of patients, because some tumor cell lines
secreted the gastrin precursors into the medium [62]. Gastrin antibodies used in the radio-
immuno-assay do not distinguish gastrin precursors from G-17 or G-34.
In a recent study of 23 hypergastrinaemic patients with the Zollinger-Ellison syn-
drome, pancolonoscopy revealed four patients with small benign adenomas, and in one
patient with a MEN I syndrome, an endocrine neoplasm ofthe colon [63]. This prevalence
ofcolon adenomas is not higher than expected in this age group and was not related to the
serum level ofgastrin and the duration ofthe hypergastrinemia. The finding ofthe authors
that in the hypergastrinaemic patients, the labeling index, using in vitro 5-bromod-
eoxyuridine incorporation in two colonic sites, was higher than in controls may not nec-
essarily be evidence for a mitogenic effect ofgastrin on the colonic mucosa [63], because
the control group was highly selected regarding personal and family history, colonic func-
tion and exclusion of patients with adenomas. Similar studies are warranted in patients
with pernicious anemia, because the results are in contradiction to experimental data in
rodents [44, 45, 46].
REFERENCES
1. Borch, K. Epidemiologic, clinicopathologic, and economic aspects ofgastroscopic screening of
patients with pernicious anemia. Scand. J. Gastroenterol. 21:21-30, 1986.
2. Borch, K., Renvall, H., and Liedberg, G. Gastric endocrine cell hyperplasia and carcinoid
tumors in pernicious anemia. Gastroenterology 88:638-648, 1985.
3. Borch, K., Renvall, H., Liedberg, G., and Andersen, B.N. Relations between circulating gastrin
and endocrine cell proliferation in the atrophic gastric fundic mucosa. Scand. J. Gastroenterol.
21:357-363, 1986.
4. Poynter, D., Pick, C.R., Harcourt, R.A., Selway, S.A.M., Ainge, G., Harman, I.W., Spurling,
N.W., Fluck, P.A., and Cook, J.L. Association of long lasting unsurmountable histamine H2
blockade and gastric carcinoid tumors in the rat. Gut 26:1284-1295, 1985.
5. Havu, N. Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibi-
tion ofgastric secretion. Digestion 35 (Suppl 1):42-55, 1986.
6. Elder, J.B. Inhibition of acid and gastric carcinoids. Gut 26:1279-1283, 1985.
7. Penston, J. andWormsley, K.G. Achlorhydria: hypergastrinaemia: carcinoids-a flawedhypoth-
esis? Gut 28:488-505, 1987.
8. Creutzfeldt, W. The achlorhydria-carcinoid sequence: role ofgastrin. Digestion 39:61-79, 1988.
9. Creutzfeldt, W. and Lamberts, R. Is hypergastrinaemia dangerous to man? Scand. J.
Gastroenterol. 26:179-191, 1991.192 Creutzfeldt: Consequences ofhypergastrinemia
10. HAkanson, R., Bottcher, G., Sundler, F., and Vallgren, S. Activation and hyperplasia of gastrin
and enterochromaffin-like cells in the stomach. Digestion 35(Suppl 1):23-41, 1986.
11. Solcia, E., Capella, C., Fiocca, R., Rindi, G., and Rosai, J. Gastric argyrophil carcinoidosis in
patients with Zollinger-Ellison syndrome due to type 1 multiple endocrine neoplasia. A newly
recognized association. Am. J. Surg. Path. 14:503-513, 1990.
12. Cadiot, G., Laurent-Puig, P., Thuille, B., Lehy,T., Mignon, M., and Olschwang, S. Is the multi-
ple endocrine neoplasia type 1 gene a suppressor for fundic argyrophil tumors in the Zollinger-
Ellison syndrome? Gastroenterology 105:579-582, 1993.
13. Mattson, H., Havu, N., Brautigam, J., Carlsson, K., Lundell, L., and Carlsson, E. Partial cor-
pectomy results in hypergastrinaemia and development ofgastric ECLcell carcinoids in the rat.
Gastroenterology 100:311-319, 1991.
14. Havu, N., Mattsson, H., Ekman, L., and Carlsson, E. ECL-cell carcinoids in the rat gastric
mucosa following long-term administration ofranitidine. Digestion 45:189-195, 1990.
15. Spencer, A.J., Bartolt, T.A., Henry, D.C., Eason, C.T., Sauerschell, R.J., and Bonner, F.W.
Gastric morphological changes including carcinoid tumors in animals treated with a potent
hypolipidemic agent, ciprofibrate. Toxicol. Path. 17:7-15, 1989.
16. Larsson, H., Carlsson, E., Mattsson, H., Lundell, L., Sundler, F., Sundell, G., Wallmark, G.,
Watanabe, T., and HAkanson, R. Plasma gastrin and gastricenterochromaffin-like cell activation
and proliferation. Studies with omeprazole and ranitidine in intact and antrectomized rats.
Gastroenterology 90:391-399, 1986.
17. Poynter, D. and Selway, S.A.M. Neuroendocrine cell hyperplasia and neuroendocrine carcino-
ma ofthe rodent fundic stomach. Mutation Res. 248:303-319, 1991.
18. Lee, A.K., DeLellis, R.A., Blount, M., Nunnemacher, G., andWolfe, H.J. Pituitary proliferative
lesions in aging male long-evans rats. A model of mixed multiple endocrine neoplasia syn-
drome. Lab. Invest. 47:595-602, 1982.
19. Lamberts, R., Creutzfeldt, W., Stockmann, F., Jacubaschke, U., Maas, S., and Brunner, G. Long-
term omeprazole treatment in man: Effects on gastric endocrine cell populations. Digestion
39:126-135, 1988.
20. Creutzfeldt, W. andLamberts, R. Inter-relationship between serumgastrin levels, gastric mucos-
al histology and gastric endocrine cell growth. Digestion 51(Suppl 1):76-81, 1992.
21. Lamberts, R., Creutzfeldt, W., Struber, H.G., Brunner, G., and Solcia, E. Long-term omeprazole
therapy in peptic ulcer disease: Gastrin, endocrine cell growth and gastritis. Gastroenterology
104:1356-1370, 1993.
22. Solcia, E., Fiocca, R., Havu, N., Dalvag, A., and Carlsson, R. Gastric endocrine cells and gas-
tritis in patients receiving long-term omeprazole treatment. Digestion 51(Suppl 1):82-92, 1992.
23. Koop, H., Frank, M., Kuly, S., Nold, R., Eissele, R. Gastric argyrophil (enterochromaffin-like),
gastrin, and somatostatin cells after proximal selective vagotomy in man. Dig. Dis. Sci. 38:295-
302, 1993.
24. Creutzfeldt, W., Stockmann, F., Conlon, J.M., Folsch, U.R., Bonatz, G., andWulfrath, M. Effect
ofshort- and long-term feeding ofomeprazole in rat gastric endocrine cells. Digestion 35(Suppl
1):84-97, 1986.
25. Grimelius, L. A silver nitrate stain for A2 cells in human pancreatic islets. Acta Soc. Med.
Uppsala 73:243-270, 1968
26. Solcia, E., Bordi, C., Creutzfeldt, W., Dayal, Y., Dayan, A.D., Falkmer, S., Grimelius, L., and
Havu, N. Histopathological classification of nonantral gastric endocrine growths in man.
Digestion 41:185-200, 1988.
27. Solcia, E., Fiocca, R., Villani, L., Gianatti, A., Cornaggia, M., Chiaravalli, A., Curzio, M., and
Capella, C. Morphology and pathogenesis ofendocrine hyperplasias, precarcinoid lesions, and
carcinoids arising in chronic atrophic gastritis. Scand. J. Gastroenterol. 26(Suppl 180):146-159,
1991.
28. Maaroos, H.I., Salupere, V., Uibo, R., Kekki, M., and Sipponen, P. Seven-year follow-up study
ofchronic gastritis in gastric ulcer patients. Scand. J. Gastroenterol. 20:198-204, 1985.
29. Havu, N., Maaroos, H.I., and Sipponen, P. Argyrophil cell hyperplasia associated with chronic
corpus gastritis in gastric ulcer disease. Scand. J. Gastroenterol. 26(Suppl 186):90-94, 1991.
30. Maton, P.N., Lack, E.E., Collen, M.J., Cornelius, M.J., David, E., Gardner, J.D., and Jensen,
R.T. The effect of Zollinger-Ellison syndrome and omeprazole therapy on gastric oxyntic
endocrine cells. Gastroenterology 99:943-950, 1990.
31. Lehy, T., Mignon, M., Cadiot, G., Elouaer-Blanc, L., Ruszniewski, P., Lewin, M.J.M, and
Bonfils, S. Gastric endocrine cell behavior in Zollinger-Ellison patients upon long-term potent
antisecretory treatment. Gastroenterology 96:1029-1040, 1989.Creutzfeldt: Consequences ofhypergastrinemia 193
32. Cadiot, G., Lehy, T., Ruszniewski, P., Bonfils, S., and Mignon, M. Gastric endocrine cell evo-
lution in patients with Zollinger-Ellison syndrome. Dig. Dis. Sci. 7:1307-1317, 1993.
33. Rindi, G., Luinetti, O., Comaggia, M., Capella, C., and Solcia, E. Three subtypes of gastric
argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study.
Gastroenterology 104:994-1006, 1993.
34. Waldum, H.L., Haugen, O.A., Isaksen, C., Mecsei, R., and Sandvik, A.K. Are diffuse gastric
carcinomas neuroendocrine tumors (ECL-omas)? Eur. J. Gastroenterol. Hepatol. 3:245-249,
1991.
35. Creutzfeldt, W. and Solcia, E. Are diffuse gastric carcinomas neuroendocrine tumors ECL-
omas? Eur. J. Gastroenterol. Hepatol. 3:179-191, 1991.
36. Morris, D.L., Watson, S.A., Durrant, L.G., and Harrison, J.D. Hormonal control ofgastric and
colorectal cancer in man. Gut 30:425-429, 1989.
37. Elsborg, L. and Mosbech, J. Pernicious anaemia as a risk factor in gastric cancer. Acta Med.
Scand. 206:315-318, 1979.
38. Svendsen, J.H., Dahl, C., Svendsen, L.B., and Christiansen, P.M. Gastric cancer risk in
achlorhydric patients. A long-term follow-up study. Scand. J. Gastroenterol. 21:16-20, 1986.
39. Brinton, L.A., Gridley, G., Hrubec, Z., Hoover, R., and Fraumeni, J.F. Cancer risk following
pernicious anaemia. Brit. J. Cancer 59:810-813, 1989.
40. Siurala, M., Lehtola, J., and Ihamiiki, T. Atrophic gastritis and its sequelae. Results of 19-23
years' follow-up examinations. Scand. J. Gastroenterol. 9:441-446, 1974.
41. Carter, D.C. Cancer after peptic ulcer surgery. Gut 28:921-923, 1987.
42. Caygill, C.P.J., Hill, M.J., Kirkham, J.S., and Northfield, T.C. Mortality from gastric cancer fol-
lowing gastric surgery for peptic ulcer. Lancet i:929-931, 1986.
43. Chu, M., Franzen, L., Sullivan, S., Wingren, S., Rehfeld, J.F., and Borch, K. Pancreatic hyper-
trophy with acinar cell nodules after longterm fundectomy in the rat. Gut 34:988-993, 1993.
44. Oscarson, J., Hakanson, R., Liedberg, G., Lundqvist., G, Sundler, F., and Thorell, J. Variated
serum gastrin concentration: trophic effects on the gastrointestinal tract ofthe rat. Acta Physiol.
Scand. 475:2-27, 1979.
45. HAkanson, R., Blom, H., Carlsson, E., Larsson, H., Ryberg, B., and Sundler, F.
Hypergastrinaemia produces trophic effects in stomach but not in pancreas and intestines.
Regul. Pept. 13:223-233, 1986.
46. Ryberg, B., Axelson, J., Hakanson, R., Sundler, F., and Mattsson, H. Trophic effects of contin-
uous infusion of [LeulS]-gastrin-17 in the rat. Gastroenterology 98:33-38, 1990.
47. Johnson, L.R. Gastrointestinal hormones and their functions. Ann. Rev. Physiol. 39:135-158,
1977.
48. Johnson, L.R. Regulation ofgastrointestinal mucosal growth. J. Surg. 3:477-487, 1979.
49. Beauchamp, R.D., Townsend, C.M., Singh, P., Glass, E.J., and Thompson, J.C. Proglumide, a
gastrin receptor antagonists, inhibits growth ofcolon cancer an enhances survival in mice. Ann.
Surg. 202:303-309, 1985.
50. Hoosein, N.M., Kiener, P.A., Curry, R.C., Rovati, L.C., McGilbra, D.K., and Brattain, M.G.
Antiproliferative effects of gastrin receptor antagonists and antibodies to gastrin on human
colon carcinoma cell lines. Cancer Res. 48:7179-7183, 1988.
51. Hoosein, N.M., Kiener, P.A., Curry, R.C., and Brattain, M.G. Evidence for autocrine growth
stimulation of cultured colon tumor cells by a gastrin/cholecystokinin-like peptide. Exp. Cell
Res. 186:15-21, 1990.
52. Graffner, H., Singh, G., Chaudry, I., and Milson, J.W. Omeprazole-induced hypergastrinemia
does not influence growth ofcolon carcinoma. Dig. Dis. Sci. 37:485-489, 1992.
53. Singh, P., Townsend, C.M., Thompson, J.C., Narayan, S., and Guo, Y.S. Gut hormones in colon
cancer: past and prospective studies. Cancer J. 3:28-33, 1990.
54. Smith, J.P., Kramer, S.T., and Demers, L.M. Effects of gastrin and difluoromethylornithine on
growth ofhuman colon cancer. Dig. Dis. Sci. 38:520-528, 1993.
55. Talley, N.J, Chute, C.G., Larson, D.E., Epstein, R., Lydick, E.G., and Melton, L.J. Risk of col-
orectal adenocarcinoma in pernicious anemia. Ann. Intern. Med. 111:738-742, 1989.
56. Smith, J.P., Wood, J.G., and Solomon, T.E. Elevated gastrin levels in patients with colon cancer
or adenomatous polyps. Dig. Dis. Sci. 34:171-174, 1989.
57. Suzuki, H., Matsumoto, K., andTerashima, H. Serum levels ofgastrin in patients with colorec-
tal neoplasia. Dis. Colon Rectum 31:716-717, 1988
58. Kaufmann, H.P. and Ottenjann, R. Serum-Nuchtern-Gastrin-Werte bei Kolonadenomen und
kolorektalen Karzinomen. Z. Gastroenterol. 29:527-528, 1991.
59. Yapp, R., Modlin, I.M., Kumar, R.R., Binder, H.J., and Dubrow, R. Gastrin and colorectal can-
cer-evidence against an association. Dig. Dis. Sci. 37:481-484, 1992.194 Creutzfeldt: Consequences ofhypergastrinemia
60. Seitz, J.F., Giovannini, M., Gouvernet, J., and Gauthier, A.P. Elevated serum gastrin levels in
patients with colorectal neoplasia. J. Clin. Gastroenterol. 13:541-545, 1991.
61. Wong, K., Beardshall, K., Waters, C.M., Calam, J., and Poston, G.J. Postprandial hypergastri-
naemia in patients with colorectal cancer. Gut 32:1352-1354, 1991.
62. van Solinge, W.W., Nielsen, F.C., Friis-Hansen, L., Falkmer, U.G., and Rehfeld, J.F. Expression
but incomplete maturation of progastrin in colorectal carcinomas. Gastroenterology 104:1099-
1107, 1993.
63. Sobhani, I., Lehy, T., Laurent-Puig, P., Cadiot, G., Ruszniewski, P., and Mignon, M. Chronic
endogenous hypergastrinemia in humans: evidence for a mitogenic effect on the colonic
mucosa. Gastroenterology 105:22-30, 1993.